ZP9830
Code ZP9830
Zealand Pharma's designed peptide Kv1.3 blocker. Clean single and multiple dose phase 1 safety data in 2026; a phase 1b in plaque psoriasis is under way.
ZP9830 comes from Zealand Pharma and sits in the Immune class on the board. Route: injection under the skin. Use tracked here: Immune mediated inflammatory diseases, starting with plaque psoriasis. It stands at Phase 1 on the board, with 1 news move logged; the latest is dated 24 Oct 2026.
- 05ApprovedCleared for sale in at least one major market for this use.
- 04FiledApplication submitted to a regulator and under review.
- 03Phase 3Large confirmatory trials meant to support a filing.
- 02Phase 2Does it work at all, and at which dose? Hundreds of patients.
- 01Phase 1Here now
- Company
- Zealand Pharma
- Mechanism
- Selective blocker of the Kv1.3 potassium channel on effector memory T cells
- Given as
- injection under the skin
- Lead use on the board
- Immune mediated inflammatory diseases, starting with plaque psoriasis
- Moves logged
- 1latest 9 days ago
ZP9830 news moves
-
ZP9830 phase 1 results show a clean safety run for the Zealand Kv1 3 blocker
Zealand Pharma's Kv1.3 ion channel blocker was well tolerated over four weeks in 32 healthy volunteers, with no serious side effects. No exposure or efficacy data were released, and a psoriasis phase 1b is now the real test.
Other immune molecules on the board, with their current stage.